New Betamab therapeutics Logo

“Betamab is dedicated to the development of a new class of therapeutics – betabodies – against diseases  with large unmet medical need.”


Learn more about the science of our drug discovery efforts. 


Meet the team

R&D Programs

Our initial research programs

Latest news

ALK buys shares in new biotech firm with experienced leader

A one-year-old biotech firm can now count one of Denmark’s largest pharmaceutical companies among its owners. ALK hopes the company is sitting on effective allergy treatment.

ALK is a global allergy solutions company, with a wide range of allergy treatments, products, and services that meet the unique needs of allergy sufferers, their families, and healthcare professionals.


Key publication for company technology

Computational Evolution of Threonine-Rich β-Hairpin Peptides Mimicking Specificity and Affinity of Antibodies

The development of recognition molecules with antibody-like properties is of great value to the biotechnological and bioanalytical communities. The recognition molecules presented here are peptides with a strong tendency to form β-hairpin structures, stabilized by alternate threonines, which are located at one face of the peptide.